Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: A proposal for clinical application

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Pozzo, Federico ^a   Peragine, Nadia ^b   Bomben, Riccardo ^a   Zucchetto, Antonella ^a   Rossi, Francesca Maria ^a   Degan, Massimo ^a   Rossi, Davide ^c   Chiarenza, Annalisa ^d   Grossi, Alberto ^e   Di Raimondo, Francesco ^d   Zaja, Francesco ^f   Pozzato, Gabriele ^g   Secchiero, Paola ^h   Gaidano, Gianluca ^c   Del Poeta, Giovanni ⁱ   Zauli, Giorgio ^j   Foà, Robin ^b   Guarini, Anna ^b   Gattei, Valter ^a   Dal Bo, Michele ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d Ferrarotto Hospital   (Italy)

^e Orthopaedics Unit IFCA Institute   (Italy)

^f SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^g UNIVERSITY OF TRIESTE   (Italy)

^h UNIVERSITY OF FERRARA   (Italy)

ⁱ UNIVERSITY OF ROME TOR VERGATA   (Italy)

^j INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

more..

Author keywords

CLL; Prognosis; TP53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; MESSENGER RNA; NUTLIN 3; PROTEIN P53;

ANALYZER; ARTICLE; CELL STRAIN HL 60; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC KIT; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE ACTIVATION; GENE DISRUPTION; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN DEFECT; RAJI CELL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; COHORT STUDIES; GENES, P53; GENOTYPE; HL-60 CELLS; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PIPERAZINES; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84887041547     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-83     Document Type: Article

References (39)

1. Chronic Lymphocytic Leukemia. Chiorazzi N, Rai KR, Ferrarini M, N Engl J Med 2005 352 804 815 10.1056/NEJMra041720 15728813 (Pubitemid 40271175)
2. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P, Lancet 2007 370 230 239 10.1016/S0140-6736(07)61125-8 17658394 (Pubitemid 47069536)
3. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Blood 1995 85 1580 1589 7888675
4. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn IW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC, J Clin Oncol 2007 25 799 804 10.1200/JCO.2006.08.3089 17283363 (Pubitemid 350010635)
5. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, Kern W, Haferlach T, Haferlach C, Leukemia 2009 23 117 124 10.1038/leu.2008.274 18843282
6. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. Gonzalez D, Martinez P, Wade R, Hockley S, Oscier D, Matutes E, Dearden CE, Richards SM, Catovsky D, Morgan GJ, J Clin Oncol 2011 29 2223 2229 10.1200/JCO.2010.32.0838 21483000
7. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, De PL, Spina V, Gattei V, Capello D, Forconi F, Lauria F, Gaidano G, Clin Cancer Res 2009 15 995 1004 10.1158/1078-0432.CCR-08-1630 19188171
8. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A, Denzel T, Winkler D, Edelmann J, Schwanen C, Dohner H, Stilgenbauer S, Blood 2008 112 3322 3329 10.1182/blood-2008-04-154070 18689542
9. TP53 mutation and survival in chronic lymphocytic leukemia. Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D, Buhler A, Edelmann J, Bergmann M, Hopfinger G, Hensel M, Hallek M, Dohner H, Stilgenbauer S, J Clin Oncol 2010 28 4473 4479 10.1200/JCO.2009.27.8762 20697090
10. Surfing the p53 network. Vogelstein B, Lane D, Levine AJ, Nature 2000 408 307 310 10.1038/35042675 11099028
11. Thymocyte apoptosis induced by p53-dependent and independent pathways. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH, Nature 1993 362 849 852 10.1038/362849a0 8479523 (Pubitemid 23132162)
12. Cancer. p53, guardian of the genome. Lane DP, Nature 1992 358 15 16 10.1038/358015a0 1614522
13. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Lotem J, Sachs L, Blood 1993 82 1092 1096 8353276 (Pubitemid 23253980)
14. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Lowe SW, Ruley HE, Jacks T, Housman DE, Cell 1993 74 957 967 10.1016/0092-8674(93)90719-7 8402885 (Pubitemid 23289454)
15. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Zenz T, Benner A, Dohner H, Stilgenbauer S, Cell Cycle 2008 7 3810 3814 10.4161/cc.7.24.7245 19098429
16. Novel CD20 monoclonal antibodies for lymphoma therapy. Cang S, Mukhi N, Wang K, Liu D, J Hematol Oncol 2012 5 64 10.1186/1756-8722-5-64 23057966
17. Therapeutic advancement of chronic lymphocytic leukemia. Lu K, Wang X, J Hematol Oncol 2012 5 55 10.1186/1756-8722-5-55 22980425
18. Genomic aberrations and survival in chronic lymphocytic leukemia. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P, N Engl J Med 2000 343 1910 1916 10.1056/NEJM200012283432602 11136261 (Pubitemid 32064784)
19. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Proffitt JH, Lucas D, Grever MR, Byrd JC, Blood 2004 103 3278 3281 10.1182/blood-2003-10-3729 14726385 (Pubitemid 38525651)
20. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Dohner H, Hillmen P, van OM, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T, Leukemia 2012 26 1458 1461 10.1038/leu.2012.25 22297721
21. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Best OG, Gardiner AC, Majid A, Walewska R, Austen B, Skowronska A, Ibbotson R, Stankovic T, Dyer MJ, Oscier DG, Leukemia 2008 22 1456 1459 10.1038/sj.leu.2405092 18200038 (Pubitemid 352006096)
22. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling. Chiaretti S, Tavolaro S, Marinelli M, Messina M, Del GI, Mauro FR, Santangelo S, Piciocchi A, Peragine N, Truong S, Patten N, Ghia EM, Torrente I, De Propris MS, Nanni M, Lawrence J, Guarini A, Foa R, Genes Chromosomes.Cancer 2011 50 263 274
23. A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Johnson GG, Sherrington PD, Carter A, Lin K, Liloglou T, Field JK, Pettitt AR, Cancer Res 2009 69 5210 5217 10.1158/0008-5472.CAN-09-0627 19491257
24. Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas. Kringen P, Bergamaschi A, Due EU, Wang Y, Tagliabue E, Nesland JM, Nehman A, Tonisson N, Borresen-Dale AL, Biotechniques 2005 39 755 761 10.2144/000112000 16312222
25. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH, Castro JE, Kipps TJ, van Lier RA, van Oers MH, Eldering E, Leukemia 2005 19 427 434 10.1038/sj.leu.2403623 15674362 (Pubitemid 40403321)
26. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Mohr J, Helfrich H, Fuge M, Eldering E, Buhler A, Winkler D, Volden M, Kater AP, Mertens D, Te RD, Dohner H, Stilgenbauer S, Zenz T, Blood 2011 117 1622 1632 10.1182/blood-2010-08-300160 21115975
27. Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. Marinelli M, Peragine N, Di MV, Chiaretti S, De Propris MS, Raponi S, Tavolaro S, Mauro FR, Del GI, Guarini A, Foa R, Haematologica 2013 98 371 375 10.3324/haematol.2012.069906 22983585
28. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T, Blood 2001 98 814 822 10.1182/blood.V98.3.814 11468183
29. Te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Le Garff-Tavernier M, Merle-Beral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP, Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia Leuk: Lymphoma 2013
30. Targeting p53 by small molecules in hematological malignancies. Saha MN, Qiu L, Chang H, J Hematol Oncol 2013 6 23 10.1186/1756-8722-6-23 23531342
31. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M, Hum Mutat 2007 28 622 629 10.1002/humu.20495 17311302 (Pubitemid 46744292)
32. Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity. Zauli G, di Iasio MG, Secchiero P, Dal Bo M, Marconi D, Bomben R, Del Poeta G, Gattei V, Curr Cancer Drug Targets 2009 9 510 518 10.2174/156800909788486777 19519319
33. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Carter A, Lin K, Sherrington PD, Pettitt AR, Br J Haematol 2004 127 425 428 10.1111/j.1365-2141.2004.05223.x 15521919 (Pubitemid 39536594)
34. Functional assessment of p53 in chronic lymphocytic leukemia. Le Garff-Tavernier M, Blons H, Nguyen-Khac F, Pannetier M, Brissard M, Gueguen S, Jacob F, Ysebaert L, Susin SA, Merle-Beral H, Blood Cancer J 2011 1 5 10.1038/bcj.2011.3 22829111
35. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration. Lin K, Adamson J, Johnson GG, Carter A, Oates M, Wade R, Richards S, Gonzalez D, Matutes E, Dearden C, Oscier DG, Catovsky D, Pettitt AR, Clin Cancer Res 2012 18 4191 4200 10.1158/1078-0432.CCR-11-2936 22675167
36. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, Blood 2008 111 5446 5456 10.1182/blood-2007-06-093906 18216293
37. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L, Buccisano F, Bomben R, Dal-Bo M, Luciano F, Rossi FM, Degan M, Amadori S, Del PG, Blood 2008 111 865 873 10.1182/blood-2007-05-092486 17959854
38. The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Zucchetto A, Vaisitti T, Benedetti D, Tissino E, Bertagnolo V, Rossi D, Bomben R, Dal Bo M, Del Principe MI, Gorgone A, Pozzato G, Gaidano G, Del PG, Malavasi F, Deaglio S, Gattei V, Leukemia 2012 26 1301 1312 10.1038/leu.2011.369 22289918
39. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. Bomben R, Dal-Bo M, Benedetti D, Capello D, Forconi F, Marconi D, Bertoni F, Maffei R, Laurenti L, Rossi D, Del Principe MI, Luciano F, Sozzi E, Cattarossi I, Zucchetto A, Rossi FM, Bulian P, Zucca E, Nicoloso MS, Degan M, Marasca R, Efremov DG, Del PG, Gaidano G, Gattei V, Clin Cancer Res 2010 16 620 628 10.1158/1078-0432.CCR-09-1638 20068100